Register Login

Abiopharma

  • Home
  • About
  • Newsroom
  • Company List
  • Events
  • Automated Tools
  • Contact

News list

Biogen Inc (BIIB)

  • Event
  • July 20, 2022, 11:04 UTC
  • 24
  • 1 comments

(10% Negative) BIOGEN INC. (BIIB) Reports Q3 2022 Financial Results

Comment Full text

RPID

  • Event
  • July 20, 2022, 10:59 UTC
  • 104
  • 0 comments

New On-Demand Webinar Now Available

Comment Full text

Exelixis Inc (EXEL)

  • Event
  • July 19, 2022, 21:28 UTC
  • 25
  • 1 comments

(99% Neutral) EXELIXIS, INC. (EXEL) Announces Regulatory Update

Comment Full text

BioNTech SE (BNTX)

  • Event
  • July 19, 2022, 21:12 UTC
  • 21
  • 1 comments

(85% Positive) BioNTech SE (BNTX) Announces Clinical Development Update (Form 6-K)

Comment Full text

Aquestive Therapeutics Inc (AQST)

  • Event
  • July 19, 2022, 20:46 UTC
  • 24
  • 1 comments

(99% Neutral) Aquestive Therapeutics, Inc. (AQST) Announces New Board Appointment

Comment Full text

Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE)

  • Event
  • July 19, 2022, 20:06 UTC
  • 24
  • 1 comments

(99% Neutral) AEGLEA BIOTHERAPEUTICS, INC. (AGLE) Files Form 8-K

Comment Full text

Gracell Biotechnologies Inc (was acquired by AstraZeneca (NASDAQ: AZN) on 20/02/2024)) (GRCL)

  • Event
  • July 19, 2022, 20:03 UTC
  • 23
  • 1 comments

(99% Neutral) Gracell Biotechnologies Inc (was acquired by AstraZeneca (NASDAQ: AZN) on 20/02/2024)) (GRCL) Files Form 6-K

Comment Full text

Inovio Pharmaceuticals Inc (INO)

  • Event
  • July 19, 2022, 12:53 UTC
  • 24
  • 1 comments

(90% Positive) Inovio Pharmaceuticals, Inc. (INO) Announces Clinical Development Update

Comment Full text

Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024) (ALPN)

  • Event
  • July 19, 2022, 12:21 UTC
  • 26
  • 1 comments

(10% Negative) ALPINE IMMUNE SCIENCES, INC. (ALPN) Files Form 8-K

Comment Full text

Genmab (GMAB)

  • Event
  • July 19, 2022, 12:14 UTC
  • 23
  • 1 comments

(99% Neutral) Genmab (GMAB) Announces Clinical Development Update (Form 6-K)

Comment Full text
  • Previous
  • 553
  • 554
  • 555
  • 556
  • 557
  • Next

Search

News categories

  • Technical Exchange News(12503)
  • Event(6229)
  • SEC News(283451)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(161903)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin